Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

View Full Paper
Ask AI
Bookmark
Share

Authors

BABertrand M. AnzTennessee OncologyDWDavid Donald WrightAstraZeneca (United Kingdom)VCVivek S. ChopraGenentech

Discussion

Loading...

Member takes

Implication

Phase II trial demonstrates substantial progression-free survival and minimal residual disease in patients receiving maintenance therapy for high-tumor burden follicular lymphoma.

Key Points

  • The 12-month progression-free survival rate was 85.5% in patients treated with subcutaneous mosunetuzumab.
  • Infections were reported in 77.7% of patients, primarily with grade 1/2 severity during the treatment.
  • Subcutaneous administration of mosunetuzumab can be safely managed in outpatient settings.
  • A significant 86.4% of patients achieving complete metabolic response were minimal residual disease negative, indicating efficacy.

Cite This Study

Anz et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc5bhttps://doi.org/10.1182/blood-2025-228
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma2025 · 1 citations
  2. 2Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  3. 3Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study2025 · 6 citations
  4. 4Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study2025 · 3 citations
  5. 5Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis2025 · 2 citations